Коровин С. И. Рекомбинантный интерлейкин-2 (ронколейкин) в лечении больных меланомой кожи / С. И. Коровин, Б. А. Толстопятов, О. А. Довгополая, А. Ю. Паливец // Лікар. справа. - 2005. - № 1-2. - С. 82-86. - Библиогр.: 6 назв. - рус.The article deals with a problem of combined use of interferon (laferon) and interleukine in patients with skin melanoma. Recombinant interleukin-2 (rlL-2) was included into the worked-out scheme. Patients with primarylocalized skin melanoma (T(2-4)N0M0) have been studied. Three groups were chosen. 901 patients of the control group underwent excision of tumor (e/t); 34 patients of the first study group (e/1) were given endolymphatic interferontherapy (ift); 35 patients of the second study group were subjected to excision of tumor followed by endolymphatic interferontherapy. One-year relapse-free survival among patients of the control group reached <$E 57,6~symbol С~1,6> %, 1st study group - <$E 70,5~symbol С~7,8> % and 2nd study group - <$E 836~symbol С~6,7> %. Total one-year survival among patients of the control group was <$E 92,1~symbol С~0,9> %, in the 1st study group - <$E 97,0~symbol С~2,9> %, in the 2nd study group - <$E 92,7~symbol С~5,0> %. Thus, the combined use of recombinant interferon (laferon and interleukin (ronkoleukin)) intreatment schemes of malignant skin melanoma was proved to be perspective. Індекс рубрикатора НБУВ: Р569.604-5
Рубрики:
Шифр НБУВ: Жс20661 Пошук видання у каталогах НБУВ
Якщо, ви не знайшли інформацію про автора(ів) публікації, маєте бажання виправити або відобразити більш докладну інформацію про науковців України запрошуємо заповнити "Анкету науковця"
|